Experience of using the drug Fuzailova
AUTHORS : Fuzailov B.N. | Makina S.K.
RELEVANT UNIVERSITIES : Moscow, Russia; Petropavlovsk, Kazakhstan
YEAR : 2006
In clinical oncological practice, since 1990, the drug “MR – anti-protein blocker”, developed by BN Fuzailov, has been used. based on the hypothesis of a
single mechanism for the nucleation of a cancer cell. The drug prevents the combination of lactic acid with phenylalanine, the formation of a complex highly
polar compound bond, the development of further processes and returns the malignant cell to the normal path of obtaining energy from glycogen. The
oncological cell receives nutrition due to the breakdown of glucose, switches to the
ancient path of energy production: anaerobic glycolysis.